Who
Amir H. Kalali
Director
Company insider
Files Form 4 as: Director, AtaiBeckley; Director, ATAI Life Sciences; Director, Cypress Bioscience.
In numbers
- Trades disclosed
- 25
- Buys
- 1
- Sells
- 0
- Bought
- $70K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 14 Jun 2007
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyBiotechnology | SEC FORM 4 Code D | —4,666 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyBiotechnology | SEC FORM 4 Code D | —4,666 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 26 Jun 2025filed 27 Jun 2025 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —103,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —103,000 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 25 May 2022filed 27 May 2022 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 10 Sep 2021filed 13 Sep 2021 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —128,000 at $0.00 | filing |
| 22 Jun 2021filed 24 Jun 2021 | ATAI Life Sciences | SEC FORM 4 Bought | $70K4,666 at $15.00 | filing |
News
No headline names them, or the companies they trade most, lately.